Current Status of the NCI Plant and Animal Product Program

Suffness, Matthew; Douros, John

doi:10.1021/np50019a001

Cited by 204 publications

(108 citation statements)

References 5 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…77 Interest in β-lapachone (also known as ARQ 501 when the company ArQule put it into clinical trials) was prompted by its activity against a range of tumor cell lines, including breast, leukemia, and prostate lines and several multidrug-resistant lines. 78 ARQ 501 had completed seven clinical trials (as of June 2016) against a range of solid tumors, including pancreatic cancer, in combination with gemcitabine, with data on three of the trials being presented as abstracts, one at the American Society for Cancer Research (AACR) meeting in 2006, 79 and the other two at the American Society for Clinical Oncology (ASCO) meeting in 2007.…”

Section: Lapachol and Lapachonementioning

confidence: 99%

The Influence of Brazilian Biodiversity on Searching for Human Use Pharmaceuticals

Newman¹

2016

J. Braz. Chem. Soc.

View full text Add to dashboard Cite

This relatively short review will cover the history of some potential drug entities whose beginnings were from Brazilian flora and fauna that led to scientific findings many years later that could not even have been thought of at the time of their initial discovery. The first two are the discoveries of the effects of peptidic toxins from the highly poisonous snake Bothrops jararaca upon the control of bradykinins that led to the angiotensin converting enzyme inhibitors, and the identification of pederin from the blister beetle Paederus species that 50 plus years later led to brand new discoveries as the source of many marine sponge metabolites. All occurred well before the Convention on Biological Diversity (CBD), in 1992. Then come discussions on lapachol and its congeners and then the potential for the investigation of microbes that are associated with insects, plants and marine invertebrates and their control of the syntheses of novel metabolites with pharmaceutical potential. The review finishes with comments on the biodiversity programs that São Paulo State has put in place and how they are materially aiding in investigations of Brazilian flora and fauna but under conditions that are CBD-compliant.

show abstract

Section: Lapachol and Lapachonementioning

confidence: 99%

The Influence of Brazilian Biodiversity on Searching for Human Use Pharmaceuticals

Newman¹

2016

J. Braz. Chem. Soc.

View full text Add to dashboard Cite

show abstract

“…For example, Barrows and coworkers have developed a C6 rat glioma cellbased assay in a microtiter plate format and screened marine natural products [223]. This quantitative cell-based antimitotic screen is a more convenient form of a previously described assay that depends on tubulin-dependent morphological changes (sphere formation) in C6 cells following dibutyryl-cAMP treatment [224].…”

Section: Tubulinmentioning

confidence: 99%

Mechanism Targeted Discovery of Antitumor Marine Natural Products

Nagle¹,

Zhou²,

Mora³

et al. 2004

Current Medicinal Chemistry

View full text Add to dashboard Cite

Antitumor drug discovery programs aim to identify chemical entities for use in the treatment of cancer. Many strategies have been used to achieve this objective. Natural products have always played a major role in anticancer medicine and the unique metabolites produced by marine organisms have increasingly become major players in antitumor drug discovery. Rapid advances have occurred in the understanding of tumor biology and molecular medicine. New insights into mechanisms responsible for neoplastic disease are significantly changing the general philosophical approach towards cancer treatment. Recently identified molecular targets have created exciting new means for disrupting tumor-specific cell signaling, cell division, energy metabolism, gene expression, drug resistance, and blood supply. Such tumor-specific treatments could someday decrease our reliance on traditional cytotoxicity-based chemotherapy and provide new less toxic treatment options with significantly fewer side effects. Novel molecular targets and state-of-the-art molecular mechanism-based screening methods have revitalized antitumor research and these changes are becoming an ever-increasing component of modern antitumor marine natural products research. This review describes marine natural products identified using tumor-specific mechanism-based assays for regulators of angiogenesis, apoptosis, cell cycle, macromolecule synthesis, mitochondrial respiration, mitosis, multidrug efflux, and signal transduction. Special emphasis is placed on natural products directly discovered using molecular mechanism-based screening.

show abstract

“…In the future, advances in our understanding of immunology and related areas should permit the development of new selective and sensitive bioassays to guide the isolation of bioactive natural products (37,38). These continuing developments should provide the means for identifying new plant-derived antiviral, antitumor, immunostimulating, and adaptogenic agents (adaptogens reportedly increase stress tolerance) (38).…”

Section: The Role Of Plant-derived Natural Products In Modern Medicinementioning

confidence: 99%

Plant-Derived Natural Products in Drug Discovery and Development

Balandrin

Kinghorn

Farnsworth

1993

ACS Symposium Series

148

103

View full text Add to dashboard Cite

The natural world once served as the source of all medicinal agents, with higher plants constituting by far the principal sources of these. Today, higher plants continue to retain their historical significance as important sources of novel compounds useful directly as medicinal agents, as model compounds for synthetic or semisynthetic structure modifications and optimization, as biochemical and/or pharmacological probes, and as sources of inspiration for generations of synthetic organic medicinal chemists. Plant-derived compounds which have recently undergone development include the anticancer agents, taxol and camptothecin, the Chinese antimalarial drug, artemisinin, and the East Indian Ayurvedic drug, forskolin. These and many other examples serve to illustrate the continuing value of plant-derived secondary metabolites as viable compounds for modern drug development.Higher plants have served humankind as sources of medicinal agents since its earliest beginnings. In fact, natural products once served as the source of all drugs. Today, natural products (and their derivatives and analogs) still represent over 50% of all drugs in clinical use, with higher plant-derived natural products representing ca. 25% of the total. On numerous occasions, the folklore records of many different cultures have provided leads to plants with useful medicinal properties (1-11). In the past two centuries, the chemical investigation and purification of extracts of plants purported to have medicinal properties, and those used as toxins and hunting poisons in their native habitats, have yielded numerous purified compounds which have

show abstract

Current Status of the NCI Plant and Animal Product Program

Cited by 204 publications

References 5 publications

The Influence of Brazilian Biodiversity on Searching for Human Use Pharmaceuticals

The Influence of Brazilian Biodiversity on Searching for Human Use Pharmaceuticals

Mechanism Targeted Discovery of Antitumor Marine Natural Products

Plant-Derived Natural Products in Drug Discovery and Development

Contact Info

Product

Resources

About